MediciNova, Inc.  

(Public, NASDAQ:MNOV)   Watch this stock  
Find more results for MNOV
-0.02 (-0.30%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.61 - 6.80
52 week 2.62 - 10.16
Open 6.73
Vol / Avg. 63,782.00/176,590.00
Mkt cap 216.78M
P/E     -
Div/yield     -
EPS -0.35
Shares 32.26M
Beta 0.98
Inst. own 23%
Jul 29, 2016
Q2 2016 MediciNova Inc Earnings Release (Estimated) Add to calendar
Jun 9, 2016
MediciNova Inc Annual Shareholders Meeting Add to calendar
Apr 28, 2016
Q1 2016 MediciNova Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -33.18% -27.14%
Return on average equity -37.73% -32.31%
Employees 10 -
CDP Score - -


4275 Executive Sq Ste 650
LA JOLLA, CA 92037-1477
United States - Map
+1-858-3731500 (Phone)
+1-858-4040048 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.

Officers and directors

Jeffrey Himawan Ph.D. Independent Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
Yuichi Iwaki M.D., Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Ryan Selhorn Chief Financial Officer
Bio & Compensation  - Reuters
Geoffrey G. O'Brien J.D. Vice President
Age: 46
Bio & Compensation  - Reuters
Masatsune Okajima Vice President, Head - Japanese Office
Age: 47
Bio & Compensation  - Reuters
Kazuko Matsuda M.D., Ph.D. Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Yoshio Ishizaka Independent Director
Age: 75
Bio & Compensation  - Reuters
Yutaka Kobayashi Independent Director
Age: 51
Bio & Compensation  - Reuters